[ad_1] NEW DELHI: Biocon is selling branded formulations of its subsidiary Biocon Biologics to Eris Lifesciences for Rs 1,242 crore. The deal will jumpstart Eris’s entry into the over Rs 30,000-crore injectables market in India, and become a leading player in the insulins segment, with acquisition of two major brands – Basalog and Insugen. It…
[ad_1] NEW DELHI: Biocon Biologics, a subsidiary of Biocon, announced a five-year partnership with Sandoz AG providing it exclusive rights to promote, sell and distribute two biosimilars —Trastuzumab and Bevacizumab, in Australia, says a company statement. Under the agreement, Sandoz will distribute the Biocon Biologics’ brands, OGIVRI (bTrastuzumab) and ABEVMY (bBevacizumab), and facilitate the sustained…
[ad_1] NEW DELHI: Biocon Biologics, a subsidiary of Biocon has signed a distribution agreement with Sandoz, granting the company exclusive rights to promote, sell and distribute `Adalimumab BS for subcutaneous injection [FKB]’* in Japan.Based on this, Viatris has completed marketing and promotion of the product as of December 15, but will continue to provide transition…